A Message from VGXI Regarding the Coronavirus (COVID-19) Outbreak and VGXI Actions LAST UPDATED March 19, 2021 To our Valued Clients and Business Partners, VGXI recognizes your concerns regarding the potential impact of the coronavirus outbreak on our products and services. VGXI is actively monitoring the situation and will continue to provide updates as new… Read More »
VGXI Official Statement Regarding COVID-19
VGXI and Geneos Therapeutics Expand Partnership for Personalized Cancer Immunotherapies
Texas-based GMP Plasmid CDMO VGXI, Inc. and Geneos Therapeutics, Inc. Expand their Clinical Manufacturing Supply Agreement in Support of Geneos’ Ongoing GT-30 Phase Ib/IIa Clinical Trial for advanced hepatocellular carcinoma (HCC). The Woodlands, TX – VGXI, Inc., an industry leading manufacturer for pre-clinical through cGMP clinical plasmid DNA, announced that its partner Geneos Therapeutics, Inc…. Read More »
VGXI Official Update Following Winter Storm Uri
To our Valued Clients and Business Partners, Thank you for everyone’s concern regarding the severe winter storm conditions that swept through Texas during the week of 15Feb21. The VGXI offices remained closed for the week to ensure the safety of all our team members as they faced challenges from icy road conditions, power outages, and… Read More »